China: Shanghai Tightens Industry Interactions With HCPs

In August 2017, multiple departments of Shanghai government,1 led by Shanghai's Health and Family Planning Commission ("Shanghai HFPC"), jointly issued a series of administrative rules2 (collectively, "Recent Shanghai Rules") to tighten the interactions of pharmaceutical and medical device companies with health care professionals ("HCPs") working in Shanghai hospitals and to crack down on commercial bribery in the course of sale and procurement of medical products.

The Recent Shanghai Rules echoed and reinforced the existing mechanisms in two earlier rules issued by China's central government in late 2013 to combat corruption in the health care sector, i.e., the Regulations on the Establishment of Commercial Bribery Records for the Purchase and Sale of Medicines (also known as the "2013 Blacklisting Rules"), and the Nine Prohibitions for Strengthening Ethical Conduct in the Healthcare Industry (also known as the "2013 Nine Prohibitions"). However, the Recent Shanghai Rules also went further than these earlier rules and considerably expanded the scope of activities subject to restrictions.

1. Mandating Registration of Medical Representatives

China's State Council first proposed registering medical representatives ("MRs") of pharmaceutical companies in February 2017 and assigned China's Food and Drug Administration ("CFDA") the task of setting up an MR registration system. In August, the Shanghai FDA became the first local FDA to announce the draft implementing measures and solicited public comments on them. The Shanghai draft measures defined MRs as professionals who engage in communication and feedback of drug product-related information on behalf of pharmaceutical manufacturers, as well as general agents of imported drugs in China and Marketing Authorization Holders.3 An MR is allowed to engage in academic promotion and technical consultancy work when interacting with HCPs, but is forbidden to carry out the sale of drugs. Once registered in the online database administered by the Shanghai FDA, a certificate will be issued to the MR, so that he or she can interact with HCPs within the permitted range and following the prescribed procedures. Identities of registered MRs will be published and any misconduct by the MRs will also be recorded in the MR registration system.

The Shanghai MR registration measures caused extensive debate among industry stakeholders. The MR definition did not cover those individuals with similar functions but employed by non-drug manufacturers, such as drug distributors and third-party service providers of manufacturers and distributors (e.g., contract sales organizations, or "CSOs"). The definition also did not expressly cover medical device manufacturers, leaving it vague as to whether medical device MRs also need to be registered in order to legally function. The distinction between the permitted "academic promotion" and the forbidden "commercial promotion /selling" activities is also not clear. The Shanghai FDA is currently evaluating comments from the industry and is likely to clarify these issues in the upcoming final version of the MR registration measures.

2. Imposing Stringent Control over Hospital Visits and On-site Interactions with HCPs

In addition to pioneering with the MR registration system, Shanghai also created a set of procedures for Shanghai-based medical institutions to follow when receiving pharmaceutical and device company representatives at hospitals, including manufacturers and distributors of drugs, medical equipment and consumables (collectively, "Medical Products"), as well as agents and employees of these companies (collectively "Industry Representatives"). For the purpose of these rules, the broader Industry Representatives, not just MRs, need to abide by the stipulated procedures when conducting on-site visits at hospitals.

Under these rules, medical institutions shall collect from all visiting companies information related to the company, the relevant products, and the visiting employees. They must also keep ledger files of such information. Industry Representatives are allowed to interact with HCPs only within designated areas of the hospitals and are prohibited from carrying out any activities in "key areas of diagnosis and treatment," such as inpatient and outpatient departments, emergency departments, medical examination departments, medical equipment departments, pharmacy departments and IT management departments.

Hospitals are required to administer proper internal procedures for receiving Industry Representatives and must strictly follow several "rules of thumb," i.e., "reception only at specified time, specified venue, by specified persons, and followed by meeting records." All visits by Industry Representatives need to be requested beforehand and meeting details need to be decided in advance. In principle, the receiving persons from the hospitals shall consist of the staff from both the medical administrative division and the relevant clinical departments, with at least two receiving persons present together from each hospital.

Hospitals are required to keep records of Industry Representatives so as to keep track of their integrity and compliance status, and to record any irregularities or misconduct during their visits to the hospital. If any Industry Representative enters the "key areas of diagnosis and treatment" to engage in drug selling or collation of prescription statistics, upon three accumulated violations, the relevant manufacturers or distributors will be blacklisted from supplying the hospital in question and the Industry Representative's misconduct will be reported to Shanghai's municipal HFPC, FDA and the centralized procurement office. If any manufacturers or distributors are found to be blacklisted by several public hospitals, the municipal authorities will likely disqualify them from participating in collective tenders.

Meanwhile, hospitals found to have seriously violated the requirements in interacting with Industry Representatives will receive merit deductions in their periodic review by the HFPC. The responsible HCPs and hospital management personnel will also receive disciplinary warnings or actions, including, among others, possible suspension of the physician's prescription right for three to six months.

3. Strictly Enforcing the Records-Keeping Requirement under Commercial Bribery Laws and Reiterating Blacklisting Consequences

Since the introduction of the central government's 2013 Blacklisting Rules, the majority of the provincial blacklists appear to have been only sporadically maintained. To actively maintain records of commercial bribery cases and to effectively blacklist relevant stakeholders, the Recent Shanghai Rules reinforced the level-by-level violation reporting mechanism and set strict time limits on the duty to report.

Reportable commercial bribery violations are determined according to the same criteria laid out in the 2013 Blacklisting Rules, including minor to serious bribery cases in the health care sector being prosecuted or investigated by the relevant authorities. Once becoming aware of a bribery case, hospitals must report them to their supervisory governmental agency (the district level HFPC or other applicable agencies) within five working days, detailing the names of involved companies and individuals. The district level supervisory agencies shall investigate and verify the facts and names related to the violation, upon completion of which they shall further report the violations to the Shanghai HFPC within five working days. The Shanghai HFPC, within 15 working days of receiving the report, shall investigate and verify the violations according to the 2013 Blacklisting Rules.

Once bribery cases are confirmed, the records will be published online on the Shanghai HFPC's website, including information such as the company's name, business address, legal representatives or persons in charge, directly responsible persons, facts of the violation and relevant judicial decisions and penalties imposed. Within one month of publicizing the records at the Shanghai provincial level, the case information will be further reported to the National HFPC for broader dissemination.

Recent Shanghai Rules reiterated the serious consequences of blacklisting as set forth in the 2013 Blacklisting Rules. Blacklisted companies or individuals are subject to debarment from Shanghai's centralized procurement office and cannot supply Shanghai public hospitals for two years. Companies or individuals blacklisted in provinces other than Shanghai are subject to a credit points deduction in tendering to Shanghai's centralized procurement. If they are blacklisted two or more times within five years in other provinces, they are similarly subject to debarment from Shanghai's centralized procurement office and cannot supply Shanghai public hospitals for two years. Recent Shanghai Rules also made it clear, however, that if a company is blacklisted, its subsidiaries or parents as independent legal entities are not implicated or considered blacklisted.


The regulatory developments in the Recent Shanghai Rules evidence a continued emphasis by PRC authorities on curbing bribery and corruption in the health care sector from both the supply and demand sides. Other provinces are likely to model themselves on the Recent Shanghai Rules and adopt similar measures. The wider implementation of these measures may pose significantly higher compliance requirements and risks for companies operating in China's health care sector. Facing China's evolving health care anti-corruption landscape, companies are advised to closely monitor further developments and update their company policies and controls to mitigate potential risks.


1. These included, among others, the Shanghai HFPC, the Shanghai Human Resources and Social Security Bureau, the Shanghai Medical Insurance Office, and the Shanghai Food and Drug Administration.

2. Three rules were issued: (i) Opinion on Strengthening the Mechanism to Crack Down on Kickbacks in Sale of Medical Products; (ii) Administrative Provisions on Management of Commercial Bribery Records in Purchase and Sale of Medical Products; (iii) Administrative Regulations on Reception of Medical Product Manufacturers and Distributors by Shanghai Medical and Healthcare Institutions. One draft rule was announced for public comments: Provisional Measures for Implementing a Registration System of Shanghai Medical Representatives.

3. "Marketing Authorization Holders" typically refers to pharmaceutical companies which own the regulatory approvals for their drugs but do not manufacture these drugs. Details of the Marketing Authorization Holder pilot initiative can be found in our China Life Sciences Alert dated June 15, 2016.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions